Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy

Haifa Kathrin Al-Ali • 19 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Navtemadlin Ruxolitinib

Haifa Kathrin Al-Ali, MD, University Hospital of Halle, Halle, Germany, discusses KRT‑232, a murine double minute 2 inhibitor (MDM2I), for myelofibrosis relapsed or refractory (R/R) to Janus‑associated kinase (JAK) inhibitor treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Haifa Kathrin Al-Ali

Preventing or reversing transfusion dependence to improve outcomes in myelofibrosis
1:27
Preventing or reversing transfusion dependence to improve outcomes in myelofibrosis
Haifa Kathrin Al-Ali • 6 Dec 2025
Fedratinib plus CC-486, an oral HMA, in accelerated-phase myelofibrosis: the FAMy trial
2:02
Fedratinib plus CC-486, an oral HMA, in accelerated-phase myelofibrosis: the FAMy trial
Haifa Kathrin Al-Ali • 6 Dec 2025
Novel approaches to upfront management of myelofibrosis
14:17
Novel approaches to upfront management of myelofibrosis
Haifa Kathrin Al-Ali • 27 Jun 2025
Unmet needs in polycythemia vera: improving symptoms & qualify of life
2:57
Unmet needs in polycythemia vera: improving symptoms & qualify of life
Haifa Kathrin Al-Ali • 11 Jun 2023

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Haifa Kathrin Al-Ali • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Haifa Kathrin Al-Ali • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Haifa Kathrin Al-Ali • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Haifa Kathrin Al-Ali • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals